Navigation Links
QRxPharma Limited Announces A$14 Million Placement Together With a Share Purchase Plan
Date:10/1/2010

therefore cause actual results to differ materially from those contained in any forward-looking statement.  Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes.  The Company intends to co-promote its products in the US and seeks strategic partnerships for worldwide markets. QRxPharma's lead product candidate, MoxDuo®IR, is in Phase 3 clinical development and has successfully completed multiple comparative studies evaluating its efficacy and safety against equi-analgesic doses of morphine, oxycodone and Percocet® for the treatment of acute pain. QRxPharma expects to complete its Phase 3 program in Q4 CY2010 and file its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for MoxDuo IR in Q1 CY2011. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information, visit www.qrxpharma.com.


'/>"/>
SOURCE QRxPharma Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , Apr. 17, 2015 Research and Markets ... the "Medical Oxygen Systems - Global Strategic Business ... report analyzes the worldwide markets for Medical Oxygen Systems ... Liquid Oxygen Systems, Oxygen Cylinders & Regulators, and Oxygen ... the US, Canada , ...
(Date:4/17/2015)... , Apr. 17, 2015 Steven Rash , ... ), and its operating subsidiary American Seed & Oil ... presentation to investors yesterday in New York City.  Mr. ... The American Seed & Oil Company has recently ... Hippie Butter Hemp Seed Foods , the EpiVape ...
(Date:4/17/2015)... , Apr. 16, 2015 Research and Markets ... of the "Corporate Reputation of Pharma in 2014 ... edition" report to their offering. This ... from 130 patient groups with an interest in diabetes ... (and of the pharma industry as a whole) in ...
Breaking Medicine Technology:Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 4Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 5
... Aug. 30, 2011 H&P Industries, Inc., a manufacturer ... Eamonn Vize to fill the Chief Operating Officer,s (COO) ... of experience in the Pharmaceutical and Biotechnology field to ... knowledge of Pharmaceutical Operations and Validations to H&P as ...
... ® Technologies, Inc. ( www.heartsine.com ), a world leader ... Food Markets, Inc. has selected  the HeartSine Automated External ...   Wegmans Food Markets, Inc. is a major ... in the U.S. with 2010 annual sales of $5.6 billion ...
Cached Medicine Technology:Shock for Life and HeartSine® Technologies Now Exclusive Providers of Lifesaving AED Solution to Wegmans Food Markets 2Shock for Life and HeartSine® Technologies Now Exclusive Providers of Lifesaving AED Solution to Wegmans Food Markets 3
(Date:4/18/2015)... Patients who undergo radiation for a hematologic ... life, but the disease is likely to differ in ... radiation. Surviving Mesothelioma has just posted the details of ... to read it now. , Scientists from China, ... patients who had both a hematologic cancer (like lymphoma ...
(Date:4/18/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Association Annual Conference to be held May 1-2, ... , The SCAPTA Annual Conference offers educational ... services. , Representatives from Aureus Medical’s ...
(Date:4/17/2015)... April 17, 2015 John Evans, a ... on the Patio from 2 p.m. to 3 p.m. ... at 1320 Executive Ct. in Pekin, Illinois, serves older ... need some help to maintain their independence. , Becky ... tropical treats will be served during the luau. , ...
(Date:4/17/2015)... Florida Hospital Wesley Chapel, Florida Hospital at Connerton ... all selected as Top Workplaces in Tampa Bay. ... ranked number one for large businesses according to the ... partnership with an independent research firm. Florida Hospital Wesley ... in October of 2012 with a vision of excellence ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Representatives Jim ... Diagnoses and Treatment Act HR 1849 in congress on ... rates and treatment for patients with the genetic disease. ... the past, would be the first to create a ... appropriate treatment of hereditary hemorrhagic telangiectasia. This would effectively ...
Breaking Medicine News(10 mins):Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 3Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 4Health News:House Representatives Introduce Bill to Fight Genetic Disease 2
... Scalia, FDA Commissioner Andrew C.,von Eschenbach Among Featured ... D.C., WASHINGTON, Jan. 9 The Food ... the Food and Drug,Administration, will focus on the ... drug law & regulation., FDLI/FDA,s March 26-27, ...
... AlphaRx (OTC BB:ALRX -,News) stated on Tuesday that CEO ... in the open market, bringing the total number of,shares ... his,continued confidence in the Company,s future., Mr. Michael ... for,an average price of $0.24 each, increasing his holdings ...
... at the U.S. Department of Energy,s Brookhaven National Laboratory ... and gain weight while others don,t. Examining how the ... stomach is in various stages of fullness, the scientists ... overeat. Treatments that target these circuits may prove useful ...
... Margolin Named President of Blue Cross of California, ... today announced that Brian A. Sassi has been ... Consumer Business Unit, which,includes the Individual, Senior and ... of Blue Cross of California, replaces Joan,Herman, who ...
... its kind in New York. Expected results include higher ... NEW YORK, Jan. 9 Group Health Incorporated (GHI) ... Home High Value Network,project, the first of its kind in ... New York with the opportunity to become Medical,Home Practices. GHI ...
... Molecular Biology Laboratory (EMBL) have discovered that proteins that ... in making sure enough nutrients and water are absorbed ... weight loss and dehydration, the scientists report in the ... component of red blood cells and has many other ...
Cached Medicine News:Health News:51st Food and Drug Law Institute Annual Conference Focuses on Relationship Between Scientific Advances and FDA Law & Regulation 2Health News:51st Food and Drug Law Institute Annual Conference Focuses on Relationship Between Scientific Advances and FDA Law & Regulation 3Health News:Overweight people may not know when they've had enough 2Health News:Overweight people may not know when they've had enough 3Health News:WellPoint Appoints Brian A. Sassi as President and CEO of the Company's Consumer Business Unit 2Health News:WellPoint Appoints Brian A. Sassi as President and CEO of the Company's Consumer Business Unit 3Health News:GHI and HIP Launch Pilot Medical Home Network Project with Support from Commonwealth Fund 2Health News:GHI and HIP Launch Pilot Medical Home Network Project with Support from Commonwealth Fund 3Health News:Life savers in the gut 2
For the qualitative detection of group A streptococcal antigen from throat swabs....
For the qualitative detection of group A Streptococcal antigen from throat swabs...
For the qualitative detection of human Chorionic Gonadotrophin (hCG) in urine specimens...
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
Medicine Products: